The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections (UTIs ... Staphylococcus saprophyticus and Enterococcus faecalis. The most common side ...

Staphylococcus saprophyticus and Enterococcus faecalis. More than half of all women will contract this kind of UTI in their lifetime, and almost a third will battle recurring episodes. Blujepa ...

The U.S. Food and Drug Administration just approved the first new antibiotic to treat urinary tract infections in nearly ... Citrobacter freundii complex, Enterococcus faecalis, and a type of ...

In trials, the drug was effective against common UTI-causing bacteria ... Staphylococcus saprophyticus, and Enterococcus faecalis. "The approval of Blujepa is a crucial milestone, with uUTIs ...

coli) produce five to 16 times more protective capsular "slime" when Enterococcus faecalis ... coli (APEC)—cause urinary tract infections in dogs and bloodstream infections in poultry, respectively.

Background Vancomycin-resistant enterococci are a leading cause of hospital-acquired urinary tract infection and a growing concern for the clinician. The aim of this study was to evaluate the ...

EAGLE-1 trial data shows gepotidacin’s potential in treating gonorrhoea, for which no new antibiotics have been approved ...

Our experience confirms and extends the findings of a previous case series on the use of daptomycin for the treatment of VRE UTIs. The previous study [12] of 5 hospitalized patients with ...

The U.S. Food and Drug Administration just approved the first new antibiotic to treat urinary tract infections in nearly three decades ... coli, Klebsiella pneumoniae, Citrobacter freundii complex, ...